Theravance Biopharma, INC 8-K filings

Theravance Biopharma achieved non-GAAP profitability in Q4 2023, driven by increased YUPELRI sales and effective expense management, while also advancing its ampreloxetine program.

Theravance Biopharma and Mylan have reached a settlement with Orbicular Pharmaceutical Technologies, granting them a license to market a generic version of YUPELRI starting April 23, 2039.